In addition, an extension of the approval period is required for the active substances clodinafop, cyprodinil, dichlorprop-P, fenpyroximate, fosetyl, mepanipyrim, metconazole, metrafenone, pirimicarb, pyrimethanil, spinosad, triclopyr, trinexapac, triticonazole and ziram to provide the time necessary to carry out an assessment relating to endocrine disrupting properties of those active substances in accordance with the procedure set out in Articles 13 and 14 of Implementing Regulation (EU) No 844/2012.
Recital 5, Regulation (EU) 2022/378
In forcesince 4 Mar 2022
- celex=32012R0844